(Pictured above from left, Overwatch Research co-founders Graham Wilsdon, Chris Armstrong and Paul Wilsdon)
A Northern Ireland biotech start-up has been acquired by US business Benchling.
Their software has already drawn multi-million pound export deals in the US.
Clients include Boston-based Blueprint Medicines, The Institute of Cancer Research in London and a global pharmaceutical company which agreed a multi-year seven-figure licence deal.
Dr Chris Armstrong, chief executive and co-founder, said: “Our software tackles core challenges contributing to the preclinical reproducibility crisis.
"This helps biopharmaceutical companies and contract research organizations (CROs) reduce errors, increase confidence for first-in-human studies, and ultimately get drugs to patients faster.
“By incorporating our in vivo study capabilities into Benchling’s industry-leading R&D Cloud, we’ll be able to reach more scientists and help them turn initial research findings into life-saving products.”
Sajith Wickramasekara, CEO and co-founder of Benchling, said: “Overwatch impressed us with their ability to build the first truly modern product for in vivo studies that is beloved by its customers.
It participated in the Co-Founders programme run by Catalyst NI before joining Invest NI’s Propel Pre-accelerator in 2018.
The R&D support had been part-financed by the European Regional Development Fund, which is no longer available.